Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma 13Recurrence 10Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Non-Hodgkin 7Leukemia, Myeloid, Acute 7Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Mantle-Cell 5Leukemia 5Hodgkin Disease 5Neoplasms 4Myelodysplastic Syndromes 4Multiple Myeloma 4Waldenstrom Macroglobulinemia 3Lymphoma, Follicular 3Hematologic Diseases 3Sarcoma 2Primary Myelofibrosis 2Precancerous Conditions 2Mastocytosis, Systemic 2Lymphoproliferative Disorders 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell 2Leukemia, Mast-Cell 2Immunoproliferative Disorders 2Immunologic Deficiency Syndromes 2Immune System Diseases 2

Interventions

pirtobrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Syndrome × Lymphoid × Clear all
NCT05172700 2024-12-18

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Eli Lilly and Company

Approved for marketing
LymphoidOther hematologic neoplasm

Hematologic Diseases, Waldenstrom Macroglobulinemia, Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡